155 related articles for article (PubMed ID: 19864082)
1. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group.
Nguyen PL; Chen MH; Beard CJ; Suh WW; Renshaw AA; Loffredo M; McMahon E; Kantoff PW; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1046-52. PubMed ID: 19864082
[TBL] [Abstract][Full Text] [Related]
2. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
D'Amico AV; Chen MH; Renshaw AA; Loffredo M; Kantoff PW
JAMA; 2008 Jan; 299(3):289-95. PubMed ID: 18212313
[TBL] [Abstract][Full Text] [Related]
3. Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death.
D'Amico AV; Chen MH; Renshaw AA; Loffredo M; Kantoff PW
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):10-5. PubMed ID: 19395184
[TBL] [Abstract][Full Text] [Related]
4. Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations.
Nguyen PL; Chen MH; Renshaw AA; Loffredo M; Kantoff PW; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):337-41. PubMed ID: 19395186
[TBL] [Abstract][Full Text] [Related]
5. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
D'Amico AV; Manola J; Loffredo M; Renshaw AA; DellaCroce A; Kantoff PW
JAMA; 2004 Aug; 292(7):821-7. PubMed ID: 15315996
[TBL] [Abstract][Full Text] [Related]
6. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
Falchook AD; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
[TBL] [Abstract][Full Text] [Related]
8. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer.
D'Amico AV; Schultz D; Loffredo M; Dugal R; Hurwitz M; Kaplan I; Beard CJ; Renshaw AA; Kantoff PW
JAMA; 2000 Sep; 284(10):1280-3. PubMed ID: 10979115
[TBL] [Abstract][Full Text] [Related]
9. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.
Liauw SL; Stadler WM; Correa D; Weichselbaum RR; Jani AB
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):125-30. PubMed ID: 19695789
[TBL] [Abstract][Full Text] [Related]
10. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
11. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy and short-term androgen deprivation for localized prostate cancer.
Jones CU; Hunt D; McGowan DG; Amin MB; Chetner MP; Bruner DW; Leibenhaut MH; Husain SM; Rotman M; Souhami L; Sandler HM; Shipley WU
N Engl J Med; 2011 Jul; 365(2):107-18. PubMed ID: 21751904
[TBL] [Abstract][Full Text] [Related]
13. Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.
Krauss DJ; Hu C; Bahary JP; Souhami L; Gore EM; Chafe SM; Leibenhaut MH; Narayan S; Torres-Roca J; Michalski J; Zeitzer KL; Donavanik V; Sandler H; McGowan DG; Jones CU; Shipley WU
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):863-73. PubMed ID: 26104939
[TBL] [Abstract][Full Text] [Related]
14. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.
D'Amico AV; Chen MH; Renshaw AA; Loffredo B; Kantoff PW
J Clin Oncol; 2008 Jun; 26(18):2979-83. PubMed ID: 18565884
[TBL] [Abstract][Full Text] [Related]
15. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052
[TBL] [Abstract][Full Text] [Related]
16. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.
Rosenthal SA; Hunt D; Sartor AO; Pienta KJ; Gomella L; Grignon D; Rajan R; Kerlin KJ; Jones CU; Dobelbower M; Shipley WU; Zeitzer K; Hamstra DA; Donavanik V; Rotman M; Hartford AC; Michalski J; Seider M; Kim H; Kuban DA; Moughan J; Sandler H
Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):294-302. PubMed ID: 26209502
[TBL] [Abstract][Full Text] [Related]
17. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
D'Amico AV; Loffredo M; Renshaw AA; Loffredo B; Chen MH
J Clin Oncol; 2006 Sep; 24(25):4190-5. PubMed ID: 16943536
[TBL] [Abstract][Full Text] [Related]
18. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer.
D'Amico AV; Chen MH; Renshaw AA; Loffredo M; Kantoff PW
Cancer; 2008 Dec; 113(12):3290-7. PubMed ID: 18980297
[TBL] [Abstract][Full Text] [Related]
19. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base.
Amini A; Jones BL; Jackson MW; Rusthoven CG; Maroni P; Kavanagh BD; Raben D
Brachytherapy; 2016; 15(2):136-46. PubMed ID: 26825856
[TBL] [Abstract][Full Text] [Related]
20. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
